Recombinant Human AQP7 Protein, MYC/DDK-tagged
Cat.No. : | AQP7-2586H |
Product Overview : | Recombinant Human AQP7 protein, fused to MYC/DDK-tagged at C-terminus, was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
- Download
Description : | Forms a channel for water and glycerol. |
Source : | HEK293 |
Species : | Human |
Tag : | Myc&DDK |
Form : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Molecular Mass : | 37.1 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Gene Name : | AQP7 aquaporin 7 [ Homo sapiens ] |
Official Symbol : | AQP7 |
Synonyms : | AQP7L; AQP9; AQPap; GLYCQTL |
Gene ID : | 364 |
mRNA Refseq : | NM_001170 |
Protein Refseq : | NP_001161 |
MIM : | 602974 |
UniProt ID : | O14520 |
Products Types
◆ Recombinant Protein | ||
Aqp7-821M | Recombinant Mouse Aqp7 Protein, MYC/DDK-tagged | +Inquiry |
AQP7-397R | Recombinant Rat AQP7 Protein, His (Fc)-Avi-tagged | +Inquiry |
AQP7-57C | Recombinant Cynomolgus Monkey AQP7 Protein, His (Fc)-Avi-tagged | +Inquiry |
AQP7-238H | Recombinant Human AQP7 Protein, His-tagged | +Inquiry |
AQP7-652M | Recombinant Mouse AQP7 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
AQP7-104HCL | Recombinant Human AQP7 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (8)
Write a reviewthe AQP7 protein's outstanding performance in ELISA and its utility in protein electron microscopy structure analysis make it a highly recommended tool for researchers.
The reliable performance of the AQP7 protein in ELISA and its compatibility with protein electron microscopy structure analysis make it an excellent choice for a wide range of research studies.
researchers have found AQP7 protein to be highly suitable for protein electron microscopy structure analysis.
AQP7 protein is highly recommended for research applications, particularly in ELISA assays and protein electron microscopy structure analysis.
Researchers who have utilized AQP7 protein praise its exceptional performance and reliability in their experiments.
AQP7 protein's ability to maintain structural integrity during imaging facilitates the detailed visualization of protein complexes and their interactions.
it has demonstrated remarkable effectiveness in ELISA experiments, showcasing its reliability and accuracy in detecting and quantifying specific targets.
the AQP7 protein has proven to be an invaluable asset in protein electron microscopy structure analysis.
Q&As (26)
Ask a questionWhile AQP7 is most prominently expressed in adipose tissue, it is also present in other tissues throughout the body. It has been detected in tissues such as the pancreas, liver, kidney, skeletal muscle, and reproductive organs. In these tissues, AQP7 may have various physiological functions related to water and glycerol transport. Its expression levels, however, can vary between different tissues and organs.
While AQP7 is most prominently expressed in adipose tissue, it is also present in other tissues throughout the body. It has been detected in tissues such as the pancreas, liver, kidney, skeletal muscle, and reproductive organs. In these tissues, AQP7 may have various physiological functions related to water and glycerol transport. Its expression levels, however, can vary between different tissues and organs.
While AQP7 is primarily known for its role in glycerol transport, it can also facilitate water transport due to its properties as an aquaporin. However, the contribution of AQP7 to overall water regulation in the body may be relatively minor compared to other aquaporin isoforms, such as AQP1 in the kidney.
Mutations or dysregulation of AQP7 have been implicated in metabolic disorders such as obesity and type 2 diabetes. In individuals with reduced AQP7 expression or function, there may be altered glycerol metabolism in adipose tissue, leading to abnormal lipid storage and potentially contributing to insulin resistance and metabolic imbalances.
Yes, AQP7 has been shown to play a role in lipid metabolism. It facilitates the movement of glycerol, a component of triglycerides, across cell membranes in adipose tissue. A deficiency in AQP7 has been associated with altered lipid metabolism and increased fat accumulation in certain studies.
Yes, AQP7 has been shown to play a role in lipid metabolism. It facilitates the movement of glycerol, a component of triglycerides, across cell membranes in adipose tissue. A deficiency in AQP7 has been associated with altered lipid metabolism and increased fat accumulation in certain studies.
Yes, there is ongoing research aimed at exploring the therapeutic potential of targeting AQP7 in metabolic disorders. This includes studying the mechanisms underlying AQP7 regulation and function, as well as determining strategies to modulate its expression or activity. Additionally, researchers are investigating the effects of pharmacological agents or interventions that can indirectly affect AQP7 function to improve metabolic health.
AQP7 has been investigated as a potential biomarker for certain diseases. For example, in obesity and metabolic disorders, altered AQP7 expression levels in adipose tissue have been associated with disease progression. Additionally, AQP7 expression changes have been observed in certain cancers, as mentioned earlier. However, the use of AQP7 as a biomarker is still in the exploratory stages, and more research is required to determine its diagnostic or prognostic value for specific diseases.
AQP7 has been investigated as a potential biomarker for certain diseases. For example, in obesity and metabolic disorders, altered AQP7 expression levels in adipose tissue have been associated with disease progression. Additionally, AQP7 expression changes have been observed in certain cancers, as mentioned earlier. However, the use of AQP7 as a biomarker is still in the exploratory stages, and more research is required to determine its diagnostic or prognostic value for specific diseases.
Yes, several genetic variants and mutations in the AQP7 gene have been identified in individuals with metabolic disorders. These include single-nucleotide polymorphisms (SNPs) that may be associated with an increased risk of obesity, insulin resistance, and type 2 diabetes. However, the precise functional consequences of these genetic variations and their role in disease development are still being elucidated.
Yes, AQP7 has been found to interact with other proteins that participate in glycerol metabolism or adipocyte function. For example, it interacts with Perilipin-1, a protein involved in lipid droplet formation and regulation. This interaction suggests a potential role of AQP7 in lipid storage and adipocyte physiology. Moreover, AQP7 may interact with other aquaporin family members or transporters to modulate glycerol transport across membranes.
Yes, there have been studies examining the potential link between AQP7 and diabetes or insulin resistance. One study found that AQP7 expression in adipose tissue was decreased in individuals with type 2 diabetes compared to healthy controls. Another study suggested that AQP7 may play a role in the regulation of glucose metabolism, as mice lacking AQP7 exhibited impaired glucose tolerance and insulin resistance. These findings suggest that AQP7 may be involved in the development of diabetes and insulin resistance, but more research is needed to fully understand the mechanisms and potential therapeutic implications.
Yes, there have been studies examining the potential link between AQP7 and diabetes or insulin resistance. One study found that AQP7 expression in adipose tissue was decreased in individuals with type 2 diabetes compared to healthy controls. Another study suggested that AQP7 may play a role in the regulation of glucose metabolism, as mice lacking AQP7 exhibited impaired glucose tolerance and insulin resistance. These findings suggest that AQP7 may be involved in the development of diabetes and insulin resistance, but more research is needed to fully understand the mechanisms and potential therapeutic implications.
Yes, there are some studies that have explored the potential involvement of AQP7 in cancer development and progression. It has been suggested that AQP7 expression may be altered in certain cancers, including breast cancer, ovarian cancer, and gastric cancer. Some studies have shown that overexpression of AQP7 can promote tumor growth and metastasis, while others have indicated that AQP7 may have tumor-suppressive effects. The exact mechanisms by which AQP7 influences cancer biology are still being investigated and further research is needed in this area.
Yes, there are some studies that have explored the potential involvement of AQP7 in cancer development and progression. It has been suggested that AQP7 expression may be altered in certain cancers, including breast cancer, ovarian cancer, and gastric cancer. Some studies have shown that overexpression of AQP7 can promote tumor growth and metastasis, while others have indicated that AQP7 may have tumor-suppressive effects. The exact mechanisms by which AQP7 influences cancer biology are still being investigated and further research is needed in this area.
AQP7 has been found to be expressed in reproductive organs such as the testes and ovaries, suggesting a potential role in fertility. However, the specific impact of AQP7 alterations on reproductive health or fertility is not yet fully understood and requires further investigation. It is possible that disruptions in AQP7-mediated glycerol transport could affect lipid metabolism in reproductive tissues, potentially influencing reproductive function.
The potential therapeutic targeting of AQP7 in metabolic disorders is an area of active research. Modulating AQP7 expression or function could potentially be explored as a strategy to improve metabolic health and treat conditions such as obesity and type 2 diabetes. However, more research is needed to understand the specific mechanisms and develop effective therapeutic interventions for targeting AQP7 in these disorders.
It is possible that changes in AQP7 expression or function could contribute to fluid imbalance disorders such as edema, although the exact role of AQP7 in these conditions is not well-defined. Edema can result from a disturbance in fluid balance, and since AQP7 is involved in water transport, alterations in its expression or activity may potentially affect fluid homeostasis in certain tissues or organs. However, more research is needed to determine the specific contributions of AQP7 to the development and progression of fluid imbalance disorders.
It is possible that changes in AQP7 expression or function could contribute to fluid imbalance disorders such as edema, although the exact role of AQP7 in these conditions is not well-defined. Edema can result from a disturbance in fluid balance, and since AQP7 is involved in water transport, alterations in its expression or activity may potentially affect fluid homeostasis in certain tissues or organs. However, more research is needed to determine the specific contributions of AQP7 to the development and progression of fluid imbalance disorders.
While the primary function of AQP7 is associated with fluid and glycerol transport in adipose tissue, there is some evidence suggesting its involvement in neurological disorders and brain functions. For example, AQP7 has been detected in certain areas of the brain, and changes in its expression have been observed in conditions such as epilepsy and traumatic brain injury.
While the primary function of AQP7 is associated with fluid and glycerol transport in adipose tissue, there is some evidence suggesting its involvement in neurological disorders and brain functions. For example, AQP7 has been detected in certain areas of the brain, and changes in its expression have been observed in conditions such as epilepsy and traumatic brain injury.
Although the therapeutic targeting of AQP7 is an intriguing possibility, developing drugs that specifically modulate AQP7 activity is a challenging task. Aquaporins have a highly conserved structure and function, and developing selective modulators for a specific aquaporin subtype like AQP7 has proven difficult. However, ongoing research may unveil potential avenues for drug development targeting AQP7 or related pathways involved in glycerol metabolism.
Yes, there have been genetic variations and mutations identified in the AQP7 gene that are associated with diseases. For example, a specific mutation in the AQP7 gene has been linked to a rare genetic disorder called congenital generalized lipodystrophy (CGL), which is characterized by the loss of adipose tissue and metabolic abnormalities. Other genetic variations in the AQP7 gene have also been associated with different metabolic disorders, such as obesity and type 2 diabetes. These findings suggest that genetic variations in the AQP7 gene can contribute to the development of certain diseases, although more research is needed to understand the full extent of these associations.
Yes, there have been genetic variations and mutations identified in the AQP7 gene that are associated with diseases. For example, a specific mutation in the AQP7 gene has been linked to a rare genetic disorder called congenital generalized lipodystrophy (CGL), which is characterized by the loss of adipose tissue and metabolic abnormalities. Other genetic variations in the AQP7 gene have also been associated with different metabolic disorders, such as obesity and type 2 diabetes. These findings suggest that genetic variations in the AQP7 gene can contribute to the development of certain diseases, although more research is needed to understand the full extent of these associations.
There have been studies that have identified certain drugs or compounds that can modulate AQP7 expression or activity. For example, compounds such as retinoic acid and thiazolidinediones (TZDs) have been shown to increase AQP7 expression in adipose tissue. On the other hand, substances like forskolin and adrenaline have been found to decrease AQP7 expression. These findings suggest potential therapeutic strategies for targeting AQP7 in metabolic disorders, but further research is needed to fully understand the effects and clinical implications of these compounds.
There have been studies that have identified certain drugs or compounds that can modulate AQP7 expression or activity. For example, compounds such as retinoic acid and thiazolidinediones (TZDs) have been shown to increase AQP7 expression in adipose tissue. On the other hand, substances like forskolin and adrenaline have been found to decrease AQP7 expression. These findings suggest potential therapeutic strategies for targeting AQP7 in metabolic disorders, but further research is needed to fully understand the effects and clinical implications of these compounds.
Ask a Question for All AQP7 Products
Required fields are marked with *
My Review for All AQP7 Products
Required fields are marked with *
Inquiry Basket